NASDAQ
33.42USD
-0.45 (-1.33%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.3B
P/E
—
EPS
—
Beta
-2.34
52W range
19.56-36.6
Day range
32.65–34.67
Open
34.13
Prev close
33.87
Volume
383.1K
Avg volume
423.6K
Dividend
0.00
IPO
2021-02-04
https://www.globenewswire.com/news-release/2026/08/06/3340059/0/en/Assessment-of-AAE-C1INH-Disease-Burden-and-Validation-of-Clinical-Trial-Endpoints-Published-in-Frontiers-in-Immunology.html · 8/6/2026+0.60
https://www.globenewswire.com/news-release/2026/07/22/3331202/0/en/Publication-in-Clinical-Reviews-in-Allergy-Immunology-Summarizes-Decades-of-Evidence-Supporting-Bradykinin-B2-Receptor-as-a-Validated-Therapeutic-Target-in-Bradykinin-Mediated-Angi.html · 7/22/2026+0.60
https://www.globenewswire.com/news-release/2026/07/06/3322293/0/en/Pharvaris-Announces-FDA-Acceptance-of-New-Drug-Application-for-Deucrictibant-IR-for-On-Demand-Treatment-of-Hereditary-Angioedema-Attacks.html · 7/6/2026+1.00
https://www.globenewswire.com/news-release/2026/05/29/3303489/0/en/Pharvaris-to-Present-Clinical-Data-at-the-EAACI-Annual-Congress-2026.html · 5/29/2026
https://seekingalpha.com/article/4904009-pharvaris-n-v-phvs-presents-at-bank-of-america-global-healthcare-conference-2026-transcript · 5/13/2026+0.10
https://www.marketbeat.com/instant-alerts/optimizerx-q1-earnings-call-highlights-2026-05-12/ · 5/13/2026+0.70
https://www.globenewswire.com/news-release/2026/04/20/3276834/0/en/Evidence-Supporting-Combined-Use-of-Deucrictibant-IR-with-Deucrictibant-XR-Presented-at-CIIC-Spring-2026-Conference.html · 4/20/2026+0.60
https://www.zacks.com/stock/news/2799891/pharvaris-stock-gains-on-hae-drug-meeting-late-stage-study-goals?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2799891 · 12/4/2025+1.00
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
